Interestingly in this study, rosiglitazone, a member of the thiazolidinedione drug family which is sometimes used off-label in PCOS management64, was identified as a candidate drug targeting both NAMPT and SOCS3. The gene discussed is SOCS3; the disease is polycystic ovary syndrome.